Categories AlphaGraphs, Earnings, Industrials
LYFT Earnings: Lyft Q1 2024 net loss narrows on higher revenues
Ride-hailing company Lyft, Inc. (NASDAQ: LYFT) has reported a narrower net loss for the first quarter of 2024 when its revenues increased by double digits.
The San Francisco-based company posted a net loss of $31.54 million or $0.08 per share for the first three months of fiscal 2024, which marks an improvement from the prior-year period when it incurred a loss of $187.6 million or $0.50 per share.
The taxi booking platform posted an adjusted EBITDA of $59.4 million for the March quarter, compared to $22.7 million in the first quarter of 2023. The bottom line benefited from a 28% growth in revenues to $1.3 billion during the three months. At $3.7 billion, Q1 gross bookings were up 21% year-over-year. There were 21.9 million active riders at the end of the quarter, up 12% year-over-year.
Lyft’s CFO Erin Brewer said, “We continue to see demand for our platform increase and our Q1 results reflect this: we delivered strong top-line growth and had our second consecutive quarter of positive free cash flow. We’ve had a solid start to the year and we’re on track to deliver on our full-year financial goals with an improved outlook for our full-year free cash flow.”
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs